Immunocore

Historical price data

Immunocore is a UK-based, publicly traded biotech focused on developing transformative T cell receptor-based immunotherapies. Its core achievement is the 2022 launch of KIMMTRAK (tebentafusp), the first-ever approved TCR therapy, for metastatic uveal melanoma. The company is advancing a broad pipeline of bispecific candidates across oncology, virology (HBV, HIV), and autoimmunity using its modular ImmTAX platform, positioning it as a leader in next-generation targeted immunomodulation.

Proprietary ImmTAX platform, a modular bispecific T cell receptor technology that uses an affinity-enhanced TCR to target intracellular disease markers presented by HLA and an anti-CD3 effector to recruit and activate T cells, enabling immune system tuning for cancer, viral infections, and autoimmunity.

17 drugs in pipeline, 3 in Phase 3

Total raised: $618M

Competes with other TCR therapy developers (Adaptimmune, TScan) and bispecific T cell engager companies. Key differentiation is its first-approved TCR therapy, a proprietary high-affinity TCR discovery platform targeting intracellular proteins, and a modular approach applicable to oncology, virology, and autoimmunity.